CCL22 and neoplasm: Du et al. used spatial transcriptomics to show that CCL17 and CCL22, which encode the dominant ligands for CCR4, are upregulated within the tumor microenvironment of nTFHL-AI, suggesting that anti-CCR4 therapies such as mogamulizumab may have activity in this disease [275].